Acute Kidney Injury Secondary to Pegylated Liposomal Doxorubicin-Associated Renal-limited Thrombotic Microangiopathy
The emergence of pegylated liposomal doxorubicin (PLD) as a preferred treatment for various malignancies, because of its reduced cardiotoxicity compared with conventional doxorubicin, has raised significant interest. However, the association between PLD and thrombotic microangiopathy (TMA) remains a...
Saved in:
| Main Authors: | Tarek S. Karam, Mrinalini Sarkar, Jonathan E. Zuckerman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Kidney Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059525000342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells
by: Annalisa Carretta, et al.
Published: (2024-09-01) -
The outcome of thrombotic microangiopathy in kidney transplant recipients
by: Kanza Haq, et al.
Published: (2024-11-01) -
Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01) -
Clinical value of the renal pathologic scoring system in complement-mediated thrombotic microangiopathy
by: Fei-Fei Chen, et al.
Published: (2023-12-01) -
Diffuse Erythematous Follicular Eruption Induced by Pegylated Liposomal Doxorubicin
by: Zhong L, et al.
Published: (2025-04-01)